Estrogen (ER) and progesterone (PgR) receptors were measured simultaneously in 1144 consecutive breast cancer patients to determine the distribution of patients according to receptor and menopausal status when receptor occurrence rates were considered. The prognostic signicance of PgR, either alone or in association with ER, was studied on 187 consecutive breast cancer patients treated only by radical mastectomy. All the cases, as regards axillary node status, were pathologically assessed as node negative. These patients did not receive any adjuvant treatment after mastectomy. At 36 months after mastectomy, the follow-up indicated that PgR- patients have a worse prognosis than PgR+ ones. This is evident when PgR alone is considered as a prognostic factor as well as when it is used to identify, within ER+ cases, those with a higher probability of relapse. In conclusion, it can be stated that although PgR status is an independent prognostic factor, it is useful to evaluate ER and PgR simultaneously for better patient management.
Get full access to this article
View all access options for this article.
References
1.
AntoniadesK., SpectorM.: Quantitative estrogen receptor values and growth of carcinoma of the breast before surgical intervention.Cancer, 50: 793–796, 1982.
2.
BertuzziA., VezzoniP., RonchiE.: Prognostic importance of progesterone receptors alone or in combination with estrogen receptors in node-negative breast carcinoma.Proc. Am. Assoc. Cancer Res. & Am. Soc. Clin. Oncol., 22: 447, 1981.
3.
BishopH.M., EistoneC.A., BlarneyR.W., HaybittleJ.L., NicholsonR.I., GriffithsK.: Relationship of estrogen receptor status to survival in breast cancer.Lancet, 2: 283–284, 1979.
4.
BonadonnaG., RossiA., ValagussaP., BanfiA., VeronesiU.: The CMF program for operable breast cancer with positive axillary nodes.Cancer, 39: 2904–2905, 1977.
5.
BradfordM.M.: A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein dye binding.Anal. Biochem., 72: 248–254, 1976.
6.
ClarkG.M., McGuireW.L., HubayC.A., PearsonO.H., MarshallJ.S.: Comparison of progesterone receptor with estrogen receptor in predicting disease free survival in stage II breast cancer patients (meeting abstract). Fifth Annual Breast Cancer Symposium, San Antonio, November 5–6, 1982.
7.
CookeT., GeorgeD., ShieldsR., MaynardP., GriffithsK.: Estrogen receptor status and prognosis in early breast cancer.Lancet, 1: 995–997, 1979.
8.
CookeT., GeorgeW.D., GriffithsK.: Possible tests for selection of adjuvant systemic therapy in early cancer of the breast.Br. J. Surg., 67: 747–750, 1980.
9.
CroweJ.P., HubayC.A., PearsonO.H., MarshallJ.S., RosenblattJ., MansourE., HermannR.E., JonesJ.S., FlynnW.J., McGuireW.L. & participating investigators: Estrogen receptor status as a prognostic indicator for stage I breast cancer patients.Breast Cancer Res. Treat., 2: 171–176, 1982.
10.
De SombreE.R., CarboneP.P., JensenE.V., Mc GuireW.L., WellsS.A., WittliffJ.L., LipsettH.B.: Steroid receptor in breast cancer.New Engl. J. Med., 301: 1011–1012, 1979.
11.
Di FronzoG., BertuzziA., RonchiE.: An improved criterion for the evaluation of estrogen receptor binding data in human breast cancer.Tumori, 64: 259–266, 1978.
12.
FisherB.: Surgery of primary breast cancer. In: Breast Cancer. Advances in Research and Treatment, vol. 1, McGuireW.Y. (Ed.), p. 1, Plenum Press, New York, 1977.
13.
FletcherW.L., LeungB.S., DavenportC.E.: The prognostic significance of estrogen receptors in human breast cancer.Am. J. Surg., 135: 372–374, 1978.
14.
HähnelR., WoodingsT., VivianA.B.: Prognostic value of estrogen receptors in primary breast cancer.Cancer, 44: 671–675, 1979.
15.
HawinksR.A., RobertsM.M., ForrestP.M.: Estrogen receptors and breast cancer: Current status.Br. J. Surg., 67: 153–169, 1980.
16.
HeusonJ.C., LongevalE., MattheiemW.H., DeboelM.C., SylvesterR.J., LeclercqG.: Significance of quantitative assessment of estrogen receptors for endocrine therapy in advanced breast cancer.Cancer, 39: 1971–1977, 1977.
17.
HilfR., FeldsteinM.L., GibsonS.L., SavlovE.D.: The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy in women with breast cancer.Cancer, 45: 1993–2000, 1980.
18.
HorwitzK.B., McGuireW.L., PearsonO.H., SegaloffA.: Predicting response to endocrine therapy in human breast cancer: A hypothesis.Science, 189: 726–727, 1975.
19.
HorwitzK.B., McGuireW.L.: Estrogen control of progesterone receptor in human breast cancer: Correlation with nuclear processing of estrogen receptor.J. Biol. Chem., 253: 2223–2228, 1978.
20.
KnightW.A.III, LivingstonR.B., GregoryE.J., McGuireW.L.: Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer.Cancer Res., 37: 4669–4671, 1977.
21.
LeclercqG., HeusonJ.C., DeboelM.C., MattheiemW.H.: Estrogen receptors in breast cancer.A changing concept. Br. Med. J., 1: 185–189, 1975.
22.
LeclercqG., HeusonJ.C.: Therapeutic significance of sex-steroid hormone receptors in the treatment of breast cancer.Eur. J. Cancer, 13: 1205–1215, 1977.
23.
MagdelenatH., PouillartP., JouveM., PalangeT., Garcia GiraltE., BretaudeauB., AsselainB.: Progesterone receptor as a more reliable prognostic parameter than estrogen receptor in patients with advanced breast cancer (letter).Breast Cancer Res. Treat., 2: 195–196, 1982.
24.
MaynardP.V., BlarneyR.W., ElstonC.W., HayblatteJ.L., GriffithsK.: Estrogen receptor assay in primary breast cancer and early recurrence of the disease.Cancer Res., 38: 4292–4295, 1978.
25.
McGuireW.L.: Hormone receptors: Their role in predicting prognosis and response to endocrine therapy.Semin. Oncol., 5: 428–433, 1978.
26.
MeyerJ.S., RaoB.R., StevensS.C., WhiteW.L.: Low incidence of estrogen receptor in breast carcinomas with rapid rates of cellular replication.Cancer, 40: 2290–2298, 1977.
27.
PetoR., PikeM.C., ArmitageP., BreslowN.E., CoxD.R., HowardS.V., MantelN., McPhersonK., PetoJ., SmithP.G.: Design and analysis of randomized clinical trials requiring prolonged observation of each patient.II. Analysis and examples. Br. J. Cancer, 35: 1–39, 1977.
28.
PichonM.F., PalludC., BrunetM., MilgromF.: Relationship of presence of progesterone receptor to prognosis in early breast cancer.Cancer Res., 40: 3357–3360, 1980.
29.
PizzocaroG., Di FronzoG., PivaL., SalvioniR., RonchiE., CappellettiV., GiongoA., MastrobernardinoE., CozzoliC., DormiaE., MinerviniS., ZanolloA., FontanellaV., GiannoniR., MaggioniA., LasioE.: Adjunctive medroxyprogesterone acetata (LPA) to radical nephrectomy in category Mo renal cell carcinoma (RCC).Preliminary report of a prospective randomized trial. Eur. Urol., 9: 202–206, 1983.
30.
SaezS., ChauvetC., MayerM., CheixF.: Estradiol and progesterone receptor as prognostic factors in human primary breast tumors.Proc. Am. Assoc. Cancer Res. & Am. Soc. Clin. Oncol., 21: 139, 1980.
31.
SaezS., CheixF., PommatauE., MayerM.: Prognostic value of progesterone receptor in operable breast cancer (meeting abstract).J. Steroid Biochem., 17: C, 1982.
32.
SamaanN.A., BudzarA.V., AldingerK.A., SchultzP.N., YangKuo-Pao, RamsdahlM.H., MartinR.: Estrogen receptor: A prognostic factor in breast cancer.Cancer, 47: 554–560, 1981.
33.
ScatchardG.: The attraction of proteins for small molecules and ions.Ann. N.Y. Acad. Sci., 51: 660–672, 1949.
34.
SilvestriniR., DaidoneM.G., Di FronzoG.: Relationship between proliferative activity and estrogen receptors in breast cancer.Cancer, 44: 665–670, 1979.
